Loading organizations...
Key people at Cash Capital.
CASH Capital operates as an equity investment fund manager, strategically deploying capital into an expanding portfolio of deep technology companies. The firm’s investment approach is centered on fostering innovation across diverse sectors, including artificial intelligence, advanced manufacturing, and biotechnology, by providing crucial financial backing and strategic guidance to high-potential ventures. It actively cultivates a robust ecosystem around these emerging technologies.
Founded in 2011, CASH Capital was initiated by the Chinese Academy of Sciences Holding Co., Ltd. This origin reflects an foundational insight to bridge cutting-edge scientific research with industrial application and market growth. Key leadership includes Wang Ge, serving as Chairman and Managing Partner, alongside Chen Hongwu, the General Manager and Executive Partner, who guide the firm’s investment strategy and operational execution.
The firm's direct customers are its limited partners, while its portfolio companies, spanning areas such as semiconductor manufacturing, medical devices, and AI solutions, are its key beneficiaries and partners. CASH Capital’s long-term vision is to significantly contribute to the prosperity of the economic ecosystem by accelerating scientific breakthroughs and industrial transformation through its targeted investments in pioneering technology ventures.
Key people at Cash Capital.
Cash Capital has 5 tracked investments across 4 companies. The latest tracked deal is $20.0M Series A in OnQuality Pharmaceuticals in March 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 31, 2021 | OnQuality Pharmaceuticals | $20.0M Series A | — | Matrix Partners China, Shiyu Capital, Sinovation Ventures |
| Sep 18, 2020 | Baijiayun | $26.3M Series B | GP Capital | Houde Qianhai Fund, Qinglan Capital |
| Oct 28, 2019 | OnQuality Pharmaceuticals | $15.0M Series A | Boyuan Capital, Jingwei Venture Capital | — |
| Jan 5, 2018 | KBP Biosciences | $76.0M Series A | Benjamin QIU, Jianping Tang | Fred Craves, Efung Capital, Elite Capital, GF Xinde Life Science Investment Fund, Korea Investment Partners, Ping AN Ventures, Sangel Capital |
| Jan 11, 2017 | EasyStack | $50.0M Series C | Cash Capital | — |